Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 11,375 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the sale, the chief executive officer now directly owns 419,173 shares of the company’s stock, valued at $10,076,918.92. This represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $23.20 on Thursday. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The business’s 50 day moving average price is $19.06 and its 200-day moving average price is $15.95.

Institutional Trading of Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Emerald Advisers LLC increased its stake in Travere Therapeutics by 8.4% in the 4th quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock worth $37,030,000 after buying an additional 165,085 shares during the period. Geode Capital Management LLC grew its stake in Travere Therapeutics by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company’s stock worth $32,100,000 after acquiring an additional 111,256 shares in the last quarter. Finepoint Capital LP increased its position in shares of Travere Therapeutics by 0.3% during the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after acquiring an additional 5,539 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of Travere Therapeutics by 26.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after acquiring an additional 244,444 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of Travere Therapeutics by 12.0% in the third quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock valued at $15,194,000 after purchasing an additional 116,175 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TVTX. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday. Evercore ISI upped their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday. Barclays raised their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. Finally, Scotiabank increased their target price on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.